BrightInsight, provider of a global platform for biopharma and medtech regulated digital health solutions, and bioMérieux, a leader in the field of in vitro diagnostics, announced a partnership to develop and bring to market a Clinical Digital Solution for diagnostics enabling clinical decision support for disease areas across their diagnostic tests.

As healthcare providers are increasingly charged with delivering better patient outcomes at a lower total cost of care, it is critical that clinicians leverage the insights delivered by high value diagnostics in a timely, optimal manner. To address this healthcare need, bioMérieux will launch a digital solution for diagnostics leveraging the compliant BrightInsight Platform and BrightInsight Disease Management Solution; technology which can be configured to meet the highest regulated digital health Software as a Medical Device (SaMD) classifications.

“We have found in BrightInsight a partner who shares our commitment to advancing public health with innovative, customer-centric solutions. Our engagement with BrightInsight will enable us to bring our digital health solutions to market faster with the goal of improving patient outcomes,” says Brian Armstrong, senior VP, Clinical Operations, North America.

This solution will improve clinical workflows, contextualize disease awareness, and ultimately enable a more holistic patient view to support clinicians in making actionable, informed decisions. bioMérieux’s Clinical Digital Solution will launch first in the U.S., with planned global expansion.

“We are honored to partner with bioMérieux to support the development of their Clinical Digital Solution for diagnostics that include clinical decision support tools used in the ICU, to assess risk and help reduce incidence of preventable diseases,” says Kal Patel, MD, CEO & co-founder, BrightInsight. “bioMérieux is a recognized in vitro diagnostics leader, joining a stellar group of life science companies leveraging our proven, compliant BrightInsight Platform as the foundation for their transformational SaMD and digital health solutions.”

BioMérieux provides diagnostic solutions (systems, reagents, software and services) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are mainly used for diagnosing infectious diseases.

“As a global organization, we need a partner with a global footprint and platform,” says Marc Bonnet, senior VP, Global Health Data Insights at bioMérieux. “BrightInsight’s Disease Management Solution is scalable and configurable to the regulatory, privacy and security requirements of myriad healthcare markets. We look forward to working with Brightinsight to bring innovative and needed digital solutions to market.”